Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $175.33.
JAZZ has been the subject of a number of recent research reports. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Piper Sandler reaffirmed an "overweight" rating and issued a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. HC Wainwright reaffirmed a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th.
Check Out Our Latest Report on Jazz Pharmaceuticals
Insider Buying and Selling at Jazz Pharmaceuticals
In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,753 shares of company stock worth $816,289 over the last three months. Corporate insiders own 4.20% of the company's stock.
Hedge Funds Weigh In On Jazz Pharmaceuticals
A number of institutional investors have recently modified their holdings of JAZZ. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $106,936,000. Rubric Capital Management LP purchased a new position in Jazz Pharmaceuticals during the second quarter worth approximately $65,812,000. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Baupost Group LLC MA increased its position in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after purchasing an additional 440,552 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company's stock valued at $48,122,000 after buying an additional 427,246 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.
Jazz Pharmaceuticals Trading Down 1.5 %
NASDAQ JAZZ traded down $1.79 during trading on Monday, hitting $120.80. The company had a trading volume of 464,804 shares, compared to its average volume of 669,682. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17. The company has a market cap of $7.30 billion, a price-to-earnings ratio of 17.01, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. The company's fifty day moving average is $116.37 and its 200-day moving average is $111.75. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.
About Jazz Pharmaceuticals
(
Get Free ReportJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Read More
![Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)](https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&Symbol=JAZZ)
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.